What molecular identity should tesamorelin acetate CoA paperwork record?
A research CoA for tesamorelin acetate is an identity document first and a purity document second. The trivial name is not an identity. The report should state that the peptide is a synthetic growth hormone-releasing factor analogue, matching the chemical class used in published analogue evaluations, and should then give the sequence-level description that class implies: a forty-four-residue GHRH backbone, a C-terminal amide, and an N-terminal hexenoyl modification that distinguishes tesamorelin from unmodified GHRH(1-44)-NH2 (PMID:19243281; PMID:17086939; PMID:21283099). If the CoA lists only tesamorelin or a supplier catalogue code, the laboratory has not been given a testable identity claim.
Identity fields that belong beside the lot number include the amino-acid sequence, an explicit N-terminal acyl statement, C-terminal amidation, theoretical mass for that covalent structure, observed mass from ESI or MALDI, mass error in ppm or Da, and salt form (acetate). Amino-acid analysis or nitrogen content supports net peptide content, not sequence. Tandem mass spectrometry with fragment coverage is stronger than a single intact-mass match, because truncated, deletion and unmodified peptides can sit near the same average-mass window when resolution is poor.
Laboratories should record how identity was assigned. A reversed-phase peak labelled tesamorelin is a retention-time hypothesis, not a structure. Orthogonal confirmation means the same lot is examined by calibrated MS and, where resource allows, fragment-ion mapping of hexenoyl-bearing N-terminal peptides. Method, instrument class, calibration reference and acceptance window belong on the report. Vial and CoA sequences must match.
How should reversed-phase HPLC purity and related substances be read?
Chromatographic purity on a peptide CoA is almost always a relative peak-area percentage at a stated wavelength, not an absolute assay of peptide content. For tesamorelin acetate, reversed-phase HPLC with UV or diode-array detection is the usual purity method. The CoA should state column chemistry (typically C18), mobile-phase pair, ion-pair reagent if used, gradient, detection wavelength, integration events, and the system-suitability result that qualified the run. Without those parameters, a figure such as 98.5% cannot be compared between suppliers or between lots.
Related-substance reporting is as important as the main-peak percentage. A defensible table lists relative retention time, area percent, and, where known, a structural assignment: deletion or insertion sequences, diastereomers, oxidation products, deamidated species, and incompletely hexenoylated GHRH. Unidentified peaks above the reporting threshold should remain unidentified. Diode-array peak-purity indices support, but do not replace, orthogonal MS.
Acceptance criteria belong in the laboratory’s incoming-goods specification. Typical research specifications set a minimum main-peak area percent, a maximum for any single unspecified impurity, and a maximum for total related substances. Those numbers are contractual analytical limits, not biological claims. Integration choices—baseline type, rider-peak skims, exclusion of solvent fronts—change the reported purity, so the chromatogram with integration ticks should be attached.
A single HPLC method is not a complete purity statement. Tesamorelin is a long, hydrophobic, N-acylated peptide; polar truncations and late aggregates may be under-represented on one gradient. Orthogonal LC–MS extracted-ion purity shows whether the main UV peak is a single mass.
What acetate-salt checks matter when laboratories tesamorelin acetaat kopen?
The Dutch query tesamorelin acetaat kopen is a salt-form query as well as a purchase query. Acetate is not a synonym for peptide powder. It is a declared counterion that changes net peptide content, hygroscopicity, ion-pair chromatographic behaviour, and residual trifluoroacetate remaining from cleavage and preparative HPLC. A CoA that does not state the salt form is incomplete for this search intent.
Counterion documentation should include anion identity (acetate versus trifluoroacetate versus mixed), a quantitative or semi-quantitative result where available (ion chromatography, 19F NMR for TFA, or stated acetate content), and the basis of the labelled milligram amount (gross lyophilised solid versus net peptide content). Two vials with the same milligram fill can differ in peptide mass if salt and water differ. Comparisons that ignore those fields are unit errors.
Acetate lots are often produced by counterion exchange after TFA-based purification. The CoA should say whether residual TFA was measured and whether it sits below a stated limit. Residual TFA is an analytical impurity and a later HPLC interference risk. Karl Fischer water, residual solvents and cake appearance complete the solid-state description. Those fields describe the solid; they do not authorise any use.
When a laboratory does tesamorelin acetaat kopen from an Australian research vendor, the purchase order should lock the salt form. Specify tesamorelin acetate, research use only, lot-linked CoA, acetate stated, residual TFA reported if measured, and net peptide content if available. Label, CoA header and invoice must match. Substituting a TFA lot is a change of material. Tracked dispatch and batch documentation should carry the same salt descriptor.
Which mass-spectrometry results confirm tesamorelin rather than a related GHRH sequence?
Intact-mass agreement is the minimum orthogonal identity test. The CoA should report ionisation mode (almost always electrospray for this mass range), the charge-state envelope, the deconvoluted mass, and the error versus the theoretical mass of hexenoyl-GHRH(1-44)-NH2. A match to unmodified GHRH(1-44)-NH2, to a free-acid C-terminus, or to a missing hexenoyl group is a different analogue. Accepting MW consistent with tesamorelin without printed theoretical and observed values is accepting a narrative.
Published work on detection of synthetic GHRH analogues emphasises chromatographic separation coupled to mass spectrometry, including characteristic ions for the intact analogue and, where method scope allows, diagnostic fragments that locate N-terminal modification (PMID:34665524). That literature is a method reference for how identity is proven; it is not a use protocol. A research CoA will rarely match specialised bioanalytical sensitivity, but it should follow the same logic: separate, ionise, measure mass, and, if claiming sequence, show fragments.
Buyers should look for coverage of the hexenoyl-bearing N-terminal peptide, confirmation of C-terminal amidation versus free acid, and absence of a dominant unmodified GHRH mass in the same lot. MALDI-TOF with a single uncalibrated centroid is weaker than ESI with a calibrated charge envelope. High-resolution MS tightens the molecular-formula window against near-isobaric deletions.
Extracted-ion chromatograms for the target mass and for truncated or oxidised masses should agree with the UV related-substance table. A clean UV trace with many masses, or a single mass with a dirty UV trace, should not pass unchecked goods-in. Calibrant, lock mass and deconvolution settings belong in the method footer so a second laboratory can repeat the assignment.
How should Australian research buyers compare tesamorelin acetate suppliers and lot files?
Purchase intent for tesamorelin acetate in Australia is still a documentation comparison. Price per milligram is meaningless until salt form, net content, HPLC method and MS identity are aligned. A cheaper lot with an unnamed salt, no chromatogram and a single MALDI line is not equivalent to a lot with acetate declared, a related-substance table and a deconvoluted ESI mass. Compare salt, purity wavelength, related-substance threshold, MS type, mass error, water, residual TFA, and whether the CoA is lot-specific rather than a generic catalogue sheet.
Local Australian stock and tracked dispatch shorten chain of custody and make lot numbers easier to reconcile with warehouse records. ClaraScience’s differentiator for research buyers is local stock, tracked dispatch and batch documentation—not a therapeutic representation. Confirm that the CoA belongs to the vial lot you will receive, that one batch number appears on vial, CoA and dispatch note, and that replacement paperwork can be retrieved by lot.
A vendor that cannot state whether the hexenoyl group is specified, whether the C-terminus is amidated, or whether acetate was measured, is not selling a characterised analogue. Request the chromatogram and the mass spectrum, not slogans. Multi-vial and wholesale orders should remain lot-based, with one analytical package per lot.
Regulatory framing in Australia is not product registration. State research-use-only laboratory material with no representation as a therapeutic good on the purchase order. None of this page is a pathway to clinical supply. Best in this context means completeness of identity and purity evidence plus Australian stock, tracked dispatch and an auditable batch file.
What lot-traceability fields should be archived after tracked dispatch arrives?
Goods-in for tesamorelin acetate should be a checklist, not an assumption that the carton matches the website. Scan the vial label, CoA and dispatch note into the same lot folder. Transcribe lot number, catalogue code, stated salt, stated milligram fill, retest date if given, and the storage statement as printed. Do not rewrite the supplier’s identity line into a shorter nickname; truncation is how hexenoyl and acetate disappear from the record.
Archive the HPLC chromatogram and peak table, the MS spectrum, counterion and water results if supplied, method identifiers, and residual-solvent statements. File any in-house confirmatory HPLC or MS result against the same lot number, including column lot, mobile-phase recipe and calibration. Results outside the incoming specification should quarantine the vials and open a documented supplier query.
Do not pool lots in a single working container: a mixture of lots has no CoA. Keep each vial associated with its lot on the experiment sheet and leave research-use labelling visible. Relabelling as a reference standard without requalification invents a material the supplier did not provide.
Align the purchase order, invoice, CoA PDF, chromatogram filename and LIMS entry on one lot key. Retention should follow the laboratory’s procedure for research chemicals so an auditor can see that the solid used in a method was the analogue that was ordered. That is documentation practice, not a protocol for people, and it does not convert research material into a therapeutic good.
Order Tesamorelin with documentation
If this guide helped you evaluate Tesamorelin for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Tesamorelin card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Is tesamorelin acetaat kopen the same as buying a medicine?
The query is treated here as procurement of a research peptide salt. ClaraScience supplies laboratory material with lot documentation, not a therapeutic good. Identity, purity, acetate counterion and MS confirmation are the relevant checks. Nothing in this article is a clinical pathway or a handling protocol for people.
What CoA fields should be present before an Australian laboratory places an order?
A lot number matching the vial, a sequence or hexenoyl-GHRH description, an acetate salt statement, HPLC purity with method parameters and a related-substance table, orthogonal mass with theoretical versus observed values, and any water or residual-TFA result should be present. A catalogue flyer without a lot number is not a CoA.
Why does acetate versus TFA matter on a research lot?
Acetate versus trifluoroacetate changes net peptide content, residual fluorine, and ion-pair HPLC behaviour. An acetate order filled with a TFA lot is a different solid. Ask for the anion identity and, where measured, a residual-TFA limit. This is a composition question, not a use question.
Can a catalogue name replace mass-spectrometric identity?
No. Tesamorelin is a modified GHRH analogue; unmodified GHRH(1-44)-NH2, free-acid termini and missing hexenoyl groups are different covalent structures. Intact-mass agreement and, where provided, fragment evidence are the identity tests. Detection literature for synthetic GHRH analogues is built on chromatography plus MS, not on trade names (PMID:34665524).
What dispatch records should be kept with the CoA?
Keep the tracked-dispatch identifier, vial-label image, invoice and CoA in one lot file. Confirm that Australian stock lot numbers match across those documents. Do not merge lots. Retention follows the laboratory’s research-chemical procedure so the analogue used in a method remains reconstructable.
Does ClaraScience offer this material for clinical programmes?
No. Lots are research-use laboratory solids with batch paperwork. They are not medicines, are not represented as therapeutic goods, and are not supplied for any clinical programme. Analytical documentation supports identity and purity decisions in the laboratory only.
References
- PMID:19243281 — Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs — 2009
- PMID:17086939 — Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor — Curr Opin Investig Drugs — 2006
- PMID:21283099 — Tesamorelin — Nat Rev Drug Discov — 2011
- PMID:34665524 — Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Test Anal — 2021
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
